Fauci Intelligence Community Release — page 72

UNCLASSIFIED UNCLASSIFIED inserted into a recombinant bat SARSr-CoV backbone. It is likely a live vaccine not yet engineered to a more attenuated state that the program sought to create with its final version. It leaked and spread rapidly because it was aerosolized so it could efficiently infect bats in caves, but it was not ready to infect bats yet, which is why it does not appear to infect bats. The reason the disease is so confusing is because it is less a virus than it is engineered spike proteins hitch-hiking a ride on a SARSr-CoV quasispecies swarm. The closer it is to the final live attenuated vaccine form, the more likely that it has been deattentuating since initial escape in August 2019. The utility of certain countermeasures can be extrapolated from the documents:  The team selected for SARSr-CoVs that were most monoclonal antibody and vaccine resistant.  It is not practical to inoculate bats directly with shots, nor can bats get respiratory infections from droplets, so the team developed an aerosol to deliver the inoculations directly into the caves. To ensure it worked well, they developed the aerosol against masked civets.  The proposal notes that interferon, Remdesivir, and chloroquine phosphate inhibit SARSr-CoV viral replication. Because of its (now) known nature, the SARSr-CoV-WIV's illness is readily resolved with early treatment that inhibits the viral replication that spreads the spike proteins around the body (which induce a harmful overactive immune response as the body tries to clear the spikes from the ACE2 receptors). Many of the early treatment protocols ignored by the authorities work because they inhibit viral replication or modulate the immune response to the spike proteins, which makes sense within the context of what EcoHealth was creating. Some of these treatment protocols also inhibit the action of the engineered spike protein. For instance, Ivermectin (identified as curative in April 2020) works throughout all phases of illness because it both inhibits viral replication and modulates the immune response. Of note, chloroquine phosphate (Hydroxychloriquine, identified April 2020 as curative) is identified in the proposal as a SARSr-CoV inhibitor, as is interferon (identified May 2020 as curative). The gene-encoded, or "mRNA," vaccines work poorly because they are synthetic replications of the already-synthetic SARSr-CoV-WIV spike proteins and possess no other epitopes. The mRNA instructs the cells to produce synthetic copies of the SARSr-CoV-WIV synthetic spike protein directly into the bloodstream, wherein they spread and produce the same ACE2 immune storm that the recombinant vaccine does. Many doctors in the country have identified that the symptoms of vaccine reactions mirror the symptoms of the disease, which corroborates with the similar synthetic nature and function of the respective spike proteins. The vaccine recipient has no defense against the bloodstream entry, but their nose protects them from the recombinant spike protein quasispecies during "natural infection" (better termed as aerosolized inoculation). For SHSGAC Use Only - SHSGAC_COVID_119th 011834